Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Eli Lilly and : Trulicity leads mixed third quarter for Lilly; shares sink

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/06/2018 | 12:22pm EDT
FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg

(Reuters) - Eli Lilly and Co's diabetes drug Trulicity helped power higher-than-expected third-quarter profit on Tuesday, while sales of some other newer treatments fell short of Wall Street estimates.

Eli Lilly shares were off 3 percent at $106.63 in late morning trading, reversing course from pre-market gains.

The quarterly beat is encouraging, but mostly driven by lower taxes and expenses, and sales were affected by lower-than-expected revenue from new drugs, SunTrust Robinson Humphrey analyst John Boris said.

Chief Financial Officer Joshua Smiley told analysts on a conference call that the company expects 2019 sales to take a hit from the loss of patent protection on erectile dysfunction drug Cialis, but that he expects new products to "more than compensate."

He also said Lilly would consider more acquisitions similar to its recent $1.6 billion purchase of cancer drug developer Armo Biosciences.

The Indianapolis-based drugmaker raised its 2018 adjusted earnings forecast to between $5.55 and $5.60 per share, from $5.40 to $5.50 per share.

Lilly, which took its Elanco animal health unit public in September, is banking on 10 new drugs launched since 2014 to drive growth as older treatments face increasing competition.

Trulicity, which recently overtook Humalog as Lilly's top-selling medicine, had sales of $816.2 million in the quarter, above analysts' consensus estimate of $801 million, according to brokerage SunTrust.

Lilly on Monday announced that Trulicity had significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of patients with type 2 diabetes in a large clinical trial.

Results from that trial should strengthen, if not cement, Lilly's position as a leader in diabetes care, analysts said.

While Trulicity sales momentum continued in the quarter, sales of other newer medicines, including diabetes treatments Basaglar and Jardiance and the cancer drug Cyramza, all fell short of Wall Street expectations.

"The quarter was mixed, but it doesn't change much," BMO Capital Markets analyst Alex Arfaei said, noting that Lilly had faced pricing pressure in the United States.

Arfaei said the company has become more dependent on Trulicity for growth, but that he sees Lilly's drugs in the class "as the emerging gold-standard in diabetes."

Excluding one-time items, Lilly earned $1.39 per share, topping analysts' average estimate by 4 cents, according to IBES data from Refinitiv.

Revenue rose about 7 percent to $6.06 billion, edging past analysts' expectations of $6.05 billion.

Net income in the quarter more than doubled to $1.15 billion.

(Reporting by Aakash Jagadeesh Babu and Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar and Bill Berkrot)

By Aakash B and Tamara Mathias

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
03/22ELI LILLY AND COMPANY : Eli Lilly and Company calls company stockholders meeting
EQ
03/22ELI LILLY AND COMPANY : - Survey Reveals Genital Psoriasis May Reduce Patients' ..
AQ
03/21ELI LILLY AND : Survey Reveals Genital Psoriasis May Reduce Patients' Self-Confi..
PU
03/20ELI LILLY AND : NCCN Announces Six Quality Improvement Projects in Gastric Cance..
PR
03/19ELI LILLY AND : Remembering Sen. Birch Bayh
PU
03/19Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer
AQ
03/15LILLY ELI & CO : Completion of Acquisition or Disposition of Assets (form 8-K)
AQ
03/12BioNTech hires banks for IPO worth up to $800 million - sources
RE
03/12ELI LILLY AND : Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary E..
PU
03/12ELI LILLY AND : Cyramza Meets Primary Endpoint in Phase 3 Study
DJ
More news
Financials ($)
Sales 2019 25 324 M
EBIT 2019 6 846 M
Net income 2019 4 876 M
Debt 2019 6 174 M
Yield 2019 1,95%
P/E ratio 2019 26,26
P/E ratio 2020 19,65
EV / Sales 2019 5,49x
EV / Sales 2020 5,20x
Capitalization 133 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 124 $
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY10.87%132 844
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409